Compare Illumina, Inc. (ILMN) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs McCormick & Company, Incorporated — how do they compare? Illumina, Inc. trades at $191.6 (market cap $27.94B), while McCormick & Company, Incorporated trades at $52.24 (market cap $14.04B). The key difference: Illumina, Inc. is the larger of the two by market cap, and McCormick & Company, Incorporated pays a 3.68% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | MKC | |
|---|---|---|
Market Cap | $27.94B | $14.04B |
Sector | Health | Consumer Staples |
52-Week High | $194.33 | $72.81 |
52-Week Low | $91.00 | $45.60 |
Enterprise Value | $29.33B | $18.65B |
Dividend Yield | — | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
MKC trades at $52.26, up 1.08% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong profitability with a 21.91% net income margin and a low P/E of 8.6, suggesting potential undervaluation. Recent Q2 2026 earnings beat expectations, and the pending Unilever Foods deal is a key strategic focus. Cash flow from operations remains robust at $962.2 million for 2025, though net cash flow was negative $90.2 million due to financing activities.
The outlook is mixed; analyst consensus is a buy with a $59.67 price target, implying 14% upside, but technicals and modest organic growth pose risks. The transformative Unilever deal offers growth potential, yet execution risks and competitive pressures in consumer segments warrant caution. Debt reduction trends are positive, with debt-to-asset ratio improving to 30.34% in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
